Transient Ischemic Attack (TIA) and stroke are significant cerebrovascular events associated with cardiovascular toxicity. This paper examines the mechanisms and risks of TIA and stroke in relation to various medications, including combined oral contraceptives, tamoxifen, bevacizumab, antipsychotics, ponatinib, and nilotinib. These drugs, while effective in their primary indications, can increase the risk of thromboembolism and subsequent cerebrovascular events. Combined oral contraceptives alter the coagulation cascade, while tamoxifen and bevacizumab affect endothelial function and angiogenesis. Antipsychotics interact with fibrinogen and platelet function, potentially leading to a pro-thrombotic state. Tyrosine kinase inhibitors like ponatinib and nilotinib have been associated with vascular toxicity and atherosclerosis. The paper also discusses risk mitigation strategies, including dosage control, the use of anticoagulants and antiplatelets, and the role of ACE inhibitors and beta-blockers in managing cardiovascular toxicity. Understanding these mechanisms and implementing appropriate preventive measures are crucial for optimizing patient care and reducing the risk of TIA and stroke in individuals receiving these medications.